Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms
Interdisciplinary Perspectives on Infectious Diseases · 30.03.2024 · 2024 · 1-15
DOI: 10.1155/2024/9109041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Interdisciplinary Perspectives on Infectious Diseases, erschienen am 30.03.2024. Verfasst von Agostinho Alves de Lima E Silva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biology and Physiology of Microorganisms, Biomedical Institute, DMP, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Federal do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Bacterial multiresistance to drugs is a rapidly growing global phenomenon. New resistance mechanisms have been described in different bacterial pathogens, threatening the effective treatment of even common infectious diseases. The problem worsens in infections associated with biofilms because, in addition to the pathogen’s multiresistance, the biofilm provides a barrier that prevents antimicrobial access. Several “non-antibiotic” drugs have antimicrobial activity, even though it is not their primary therapeutic purpose. However, due to the urgent need to develop effective antimicrobials to treat diseases caused by multidrug-resistant pathogens, there has been an increase in research into “non-antibiotic” drugs to offer an alternative therapy through the so-called drug repositioning or repurposing. The prospect of new uses for existing drugs has the advantage of reducing the time and effort required to develop new compounds. Moreover, many drugs are already well characterized regarding toxicity and pharmacokinetic/pharmacodynamic properties. Ebselen has shown promise for use as a repurposing drug for antimicrobial purposes. It is a synthetic organoselenium with anti-inflammatory, antioxidant, and cytoprotective activity. A very attractive factor for using ebselen is that, in addition to potent antimicrobial activity, its minimum inhibitory concentration is very low for microbial pathogens.
Autor:innen und Institutionen
- Laboratory of Biology and Physiology of Microorganisms, Biomedical Institute, DMP, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro 20211-030, Brazil.
- Laboratory of Pathogenic Cocci and Microbiota, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-853, Brazil.
ORCID-Profile: Agostinho Alves de Lima E Silva, André Rio-Tinto
Förderung
- Universidade Federal do Estado do Rio de Janeiro
Zitieren
APA
Alves de Lima E Silva, A., & Rio-Tinto, A. (2024). Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms. Interdisciplinary Perspectives on Infectious Diseases, 2024, 1-15. https://doi.org/10.1155/2024/9109041
Vancouver
Alves de Lima E Silva A, Rio-Tinto A. Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms. Interdisciplinary Perspectives on Infectious Diseases. 2024;2024:1-15. doi:10.1155/2024/9109041
BibTeX
@article{AlvesdeLimaESilva2024,
author = {Alves de Lima E Silva, Agostinho and Rio-Tinto, André},
title = {Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms},
journal = {Interdisciplinary Perspectives on Infectious Diseases},
year = {2024},
volume = {2024},
pages = {1--15},
doi = {10.1155/2024/9109041}
}
EUVIMED